Navitoclax-d8
Based on 1 publication(s) in Google Scholar
Navitoclax-d8 is the d8-labeled Navitoclax (HY-10087). Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 1217620-38-6
- Formula: C47H47D8ClF3N5O6S3
- Molecular Weight:982.66
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Navitoclax-d8
More
Biological Activity
|
Bcl-2 <1 nM (Ki) |
Bcl-xL <1 nM (Ki) |
Bcl-W <1 nM (Ki) |
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1217620-38-6
-
Unlabeled Cas 923564-51-6
-
Appearance Solid
-
Molecular Weight 982.66
-
Formula C47H47D8ClF3N5O6S3
-
Color White to off-white
-
SMILES
CC(C)(C1)CCC(C2=CC=C(C=C2)Cl)=C1CN3CCN(C4=CC=C(C=C4)C(NS(=O)(C5=CC(S(C(F)(F)F)(=O)=O)=C(C=C5)N[C@@H](CSC6=CC=CC=C6)CCN7C([2H])([2H])C([2H])([2H])OC([2H])([2H])C7([2H])[2H])=O)=O)CC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. [Abstract]2025 Mar 27;16(1):3003. PMID: 40148277
Solvent & Solubility
DMSO : ≥ 25 mg/mL (25.44 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lock R, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatric blood & cancer. 2008 Jun;50(6):1181-9. [Content Brief]
[2]. Chen J, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9. [Content Brief]
[3]. Chen J, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Molecular cancer therapeutics. 2011 Dec;10(12):2340-9. [Content Brief]
[4]. Mohamad Anuar NN, et al. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent. Frontiers in pharmacology. 2020;11:564108. [Content Brief]
[5]. Wilson WH, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet. Oncology. 2010 Dec;11(12):1149-59. [Content Brief]
[6]. Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Molecular cancer therapeutics. 2012 Apr;11(4):1026-35. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0176 mL | 5.0882 mL | 10.1765 mL | 25.4412 mL |
| 5 mM | 0.2035 mL | 1.0176 mL | 2.0353 mL | 5.0882 mL | |
| 10 mM | 0.1018 mL | 0.5088 mL | 1.0176 mL | 2.5441 mL | |
| 15 mM | 0.0678 mL | 0.3392 mL | 0.6784 mL | 1.6961 mL | |
| 20 mM | 0.0509 mL | 0.2544 mL | 0.5088 mL | 1.2721 mL | |
| 25 mM | 0.0407 mL | 0.2035 mL | 0.4071 mL | 1.0176 mL |
Navitoclax-d8 Related Classifications
HY-10087S Related Classifications
Powered by Bioz